Leslie Auld Appointed to GeneNews Board of Directors

TORONTO, June 28, 2013 (GLOBE NEWSWIRE) -- GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company"), a company focused on developing and commercializing blood-based biomarker tests for the early detection of diseases and personalized health management, announced today that its Chief Financial Officer and Treasurer, Leslie Auld, has been appointed to the Company's Board of Directors.

Ms. Auld, a Chartered Professional Accountant, joined the Company in 2010. Ms. Auld is an Honours Bachelor of Arts graduate from the University of Western Ontario in Science, Pharmacology & Toxicology. In addition, she has a Master of Business Administration degree from the University of Toronto. She began her professional career in 1991 with PriceWaterhouseCoopers. She later joined Helix BioPharma Corp. where she progressed from Controller to Chief Financial Officer. In 2004, Ms. Auld joined Luminex Diagnostics (formerly TM BioScience Corp.) as Senior Director of Finance, where she focused on finance and operations during a period of growth and then held a pivotal role in the transaction that took TM BioScience private when it was acquired by Luminex.

"Leslie is an accomplished financial professional whose contributions have supported the Company's financial strategy over the last number of years," said Rory Riggs, Chair of the Board of GeneNews. "I am pleased to welcome her to the Board and look forward to continue drawing upon her experience and strong record of success working with rapidly evolving emerging public issuers in the healthcare sector as we work to launch ColonSentry® into additional regions of the US and selected global markets."

About GeneNews

GeneNews is a molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic tests through the application of functional genomics to enable early diagnosis and personalized health management. The Company has developed a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews has applied the Sentinel Principle® in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' lead product, ColonSentry®, is the world's first blood test to assess an individual's current risk for colorectal cancer. For more information on GeneNews and ColonSentry®, go to www.GeneNews.com or www.ColonSentry.com.

Forward-Looking Statements

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

CONTACT: Company Contact: Gailina Liew President & COO Office: (905) 739-2036 Mobile: (416) 844-0649 gliew@genenews.com Investor & Media Contact: Stephen Kilmer Kilmer Lucas Inc. Office: (212) 618-6347 Mobile: (905) 906-6908 stephen@kilmerlucas.comSource:GeneNews Limited